Form 8-K Revance Therapeutics, For: Nov 09
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Revance Therapeutic (RVNC) PT Lowered to $31 at Stifel
November 10, 2021 6:49 AM ESTStifel analyst Annabel Samimy lowered the price target on Revance Therapeutic (NASDAQ: RVNC) to $31.00 (from $33.00) while maintaining a Buy rating.
The analyst commented, "RVNC reported solid revenues ($19.8mn/ Cons $20.3) from steady RHA-filler sales ($18.3mn) in a seasonally difficult quarter and meaningful expansion of... More
